TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01002703
Drug: Lenalidomide, Bendamustine, Prednisone
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
Study: NCT04407000
Drug: Reference: Favipiravir 200 mg (Avigan)
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Reference Drug
Study: NCT00452543
Drug: acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
Study: NCT03355027
Drug: Atorvastatin 40Mg Tablet
Normalized name: atorvastatin 40 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT02156596
Drug: IV NSAI
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
Study: NCT02156596
Drug: NM
Normalized name: NMP
DrugBank: Methyl pyrrolidone (DB12521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
Study: NCT00452543
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
Study: NCT00965731
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
Study: NCT00965731
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
Study: NCT00965731
Drug: PF-02341066
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
Study: NCT00638378
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib 25 mg tablets taken with water twice a day.
Study: NCT00996216
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
Study: NCT01098539
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
Study: NCT01852110
Drug: MK-7622
Normalized name: MK-7622
DrugBank: MK-7622 (DB12897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7622 capsule
Study: NCT03024801
Drug: autologous platelet-rich plasma
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
Study: NCT01265732
Drug: PF-04191834
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, 100mg, dispersion
Study: NCT01265732
Drug: PF-04191834
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, 100mg, suspension
Study: NCT01265732
Drug: PF-04191834
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, 300mg, suspension
Study: NCT00709514
Drug: DCB-WH1 ointment
Normalized name: DCB
DrugBank: Dichlorobenzene (DB14046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCB-WH1 ointment (1.25%), topically applied twice daily
Study: NCT00254813
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04169321
Drug: Single Arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]-NOTA-hGZP is a PET imaging agent.
Study: NCT04714515
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An FDA approved medicine to treat asthmatic patients
Study: NCT00193323
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193323
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01616524
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 400 mg, Twice daily, 24 weeks
Study: NCT01616524
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 400 mg, Twice daily, 12 weeks
Study: NCT01616524
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 60 mg, Once daily, 12 weeks
Study: NCT01616524
Drug: Placebo matching Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks
Study: NCT00939523
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will be asked to take Lapatinib daily for six months during the research study.
Study: NCT04714515
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An FDA approved antiarthritis drug
Study: NCT04714515
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An FDA approved anti-parasitic medicine
Study: NCT01539057
Drug: Fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts
Study: NCT01539057
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
Study: NCT00299455
Drug: amoxicillin-clavulanate
Normalized name: amoxicillin-clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
Study: NCT03108833
Drug: Recombinant Human Prourokinase
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug is used for intravenous thrombolysis therapy
Study: NCT03108833
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug is used for intravenous thrombolysis therapy
Study: NCT02199379
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
Study: NCT02026479
Drug: Dexamethasone Phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg; postauricular injection
Study: NCT02026479
Drug: Dexamethasone Phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg; postauricular injection
Study: NCT02031666
Drug: JNJ-56021927 capsule
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
Study: NCT02031666
Drug: JNJ-56021927 tablet
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
Study: NCT01204853
Drug: Sitaxentan
Normalized name: Sitaxentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: sitaxentan sodium 100 mg
Study: NCT00391404
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 70 mg weekly (oral)
Study: NCT02085317
Drug: sodium nitroprusside Iontophoresis
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
Study: NCT00135603
Drug: amoxicillin/clavulanate potassium
Normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
Study: NCT00721487
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
Study: NCT03790137
Drug: Fenfluramine Hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
Study: NCT00111137
Drug: rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
Study: NCT00111137
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
Study: NCT03608501
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib capsules.
Study: NCT03608501
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide capsules.
Study: NCT03608501
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets.
Study: NCT02287272
Drug: CHF 5993 pMDI
Normalized name: CHF-6333
DrugBank: CHF-6333 (DB17815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
Study: NCT02287272
Drug: Cimetidine plus CHF5993 pMDI
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
Study: NCT01062360
Drug: Pseudoephedrine
Normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study: NCT00760578
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT00760578
Drug: MSDC-0160 90 mg
Normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT00760578
Drug: MSDC-0160 220 mg
Normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT01338792
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01338792
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01324284
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
Study: NCT02117726
Drug: Dexmedetomidine,midazolam
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02117726
Drug: Propofol,midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02848079
Drug: combined TAS-102 and TAS-OX
Normalized name: Ta
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
Study: NCT02989194
Drug: VIS410 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single intravenous fixed low dose of VIS410
Study: NCT02989194
Drug: VIS410 high dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous fixed high dose of VIS410
Study: NCT03111901
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab solution
Study: NCT03111901
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 solution
Study: NCT02024633
Drug: icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
Study: NCT02024633
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
Study: NCT03355027
Drug: Atorvastatin 80Mg Tablet
Normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT00141505
Drug: Bifeprunox
Normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02583698
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03912285
Drug: Amlodipine10mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 10mg will be administered orally twice a day for 9 days
Study: NCT03912285
Drug: Losartan potassium 100mg
Normalized name: LOSARTAN POTASSIUM 100MG TAB
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 100mg will be administered orally once a day for 9 days
Study: NCT03912285
Drug: Amlodipine plus Losartan
Normalized name: losartan and amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan
Study: NCT04687878
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU twice a day, intranasally, every day for 12 weeks
Study: NCT04525664
Drug: Amoxicillin 1000 MG
Normalized name: amoxicillin 1000 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg per os twice daily for 14 consecutive days.
Study: NCT04525664
Drug: Omeprazole 40 MG
Normalized name: omeprazole 40 MG
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg per os twice daily for 14 consecutive days.
Study: NCT04525664
Drug: Omeprazole 20 MG Oral Tablet
Normalized name: omeprazole 20 MG Oral Tablet
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
Study: NCT04300127
Drug: Pioglitazone 30 mg
Normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will received 30 mg of Pioglitazone once a day for 8 weeks
Study: NCT04096547
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rivaroxaban for stroke prevention of atrial fibrillation
Study: NCT00351117
Drug: St. John's Wort
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW in capsule form 300 mg PO TID
Study: NCT00907205
Drug: SF1126
Normalized name: SF1126
DrugBank: SF1126 (DB05210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalating with 3+ patients in each cohort
Study: NCT01082120
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet oral single dose for 10 days
Study: NCT03506815
Drug: Rivaroxaban 10 MG
Normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 10mg po daily x 90 (+/- 3 days)
Study: NCT01598051
Drug: Rivaroxaban (Xarelto_ BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients treated with Xarelto under practical manner for SPAF.
Study: NCT00860158
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Study: NCT02240160
Drug: Sativex
Normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
Study: NCT00860158
Drug: Leuprolide Acetate (LHRH Analogue)
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Study: NCT00038857
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m\^2 on day -8
Study: NCT00038857
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg on day -7
Study: NCT00038857
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/m\^2 over 4 days on days -6, -5, -4, -3
Study: NCT00038857
Drug: Rabbit ATG
Normalized name: Rabbit ATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
Study: NCT03045627
Drug: Aclarubicin
Normalized name: aclarubicin
DrugBank: Aclarubicin (DB11617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8